Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 27–Oct 4, 2026)
No FDA decision dates fall in this week, so the calendar belongs to trials: seven company-led studies have estimated primary completion dates, among them IBRX’s BCG combination in bladder cancer, ARWR’s ARO-DIMERPA in mixed hyperlipidemia and JAZZ’s zanidatamab combination. On the financing side, VKTX filed $275M of convertible notes, and it was also last week’s biggest gainer, up 36%.
🧪 Trial Catalysts & Milestones
- IBRX, 2026-09-30: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer Registry
- BIIB, 2026-09-30: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden Registry
- ARWR, 2026-09-30: Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia Registry
- JAZZ, 2026-09-30: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Registry
- IBRX, 2026-10-01: A Study to Assess Anktiva in Patients With Long Covid-19. Registry
- CORT, 2026-10-01: Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Registry
- BHVN, 2026-10-01: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Registry
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- SLDB: Phase 1, Phase 2, Active Trial in 18 days, score 62/100
- EWTX: N/A, Active Trial in 3 days, score 52/100
- SNDX: Phase 1, Recruiting in 4 days, score 50/100
💸 Dilution Watch: New Financing Filings
- VKTX: convertible notes $275M (424B5, 2026-09-25) EDGAR
- IMCC: registered direct offering (424B5, 2026-09-24) EDGAR
- BMRA: shelf registration (S-3, 2026-09-24) EDGAR
- GRML: ATM program (424B5, 2026-09-23) EDGAR
- GRML: registered direct offering (424B5, 2026-09-23) EDGAR
📈 Last Week’s Biggest Gainers
- VKTX +35.67% (volume 17.9x average)
- TWST +16.11% (volume 2.0x average)
- TNGX +14.33% (volume 2.4x average)
- IBRX +9.94% (volume 2.1x average)
- BRVE +8.90% (volume 0.7x average)
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.